Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sulfosalicylic. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 14/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.81 |
| ▸ | MEN1 | O00255 | 9/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.81 |
| ▸ | USP2 | O75604 | 8/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.81 |
| ▸ | RECQL | P46063 | 7/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.81 |
| ▸ | HPGD | P15428 | 7/20 | 0.81 |
| ▸ | THRB | P10828 | 6/20 | 0.81 |
| ▸ | MAPT | P10636 | 6/20 | 0.81 |
| ▸ | LMNA | P02545 | 4/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.81 |
| ▸ | CASP7 | P55210 | 2/20 | 0.81 |
| ▸ | CASP1 | P29466 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfosalicylic SCHEMBL29674900 | 0.90 | TDP1 (1.00) | TDP1KDM4EMEN1KMT2AUSP2 | |
| SCHEMBL1650332 | 0.88 | TDP1 (0.62) | TDP1KDM4EMEN1KMT2AUSP2 | |
| SCHEMBL12841672 | 0.88 | TDP1 (0.62) | TDP1KDM4EMEN1KMT2AUSP2 | |
| SCHEMBL3446 | 0.88 | TDP1 (0.62) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL5849023 | 0.81 | TDP1 (0.77) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL193563 | 0.81 | TDP1 (0.77) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL29365199 | 0.81 | TDP1 (0.77) | TDP1KDM4EMEN1KMT2AUSP2 | |
| SCHEMBL29487299 | 0.77 | TDP1 (0.78) | TDP1KDM4EMEN1KMT2AUSP2 | |
| SCHEMBL23247761 | 0.77 | TDP1 (0.78) | TDP1KDM4EMEN1KMT2AUSP2 | |
| SCHEMBL4015 | 0.76 | TDP1 (0.73) | TDP1KDM4EMEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117926640-B | Environment-friendly decorative paper and preparation method thereof | 浙江锦尚添彩新材料有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-117926640-A | Environment-friendly decorative paper and preparation method thereof | 浙江锦尚添彩新材料有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC | 2021-05-20 | — | — | US | disclosed |
| CN-107823629-A | Using application of the tannic acid as a series of compounds of representative in the infection of the Alphaviruses such as anti-chikungunya | 天津国际生物医药联合研究院 | 2018-03-23 | — | — | CN | disclosed |
| CN-107789358-A | Using application of the Traumatociclina as several compounds of representative in the infection of anti-Enterovirus 68 type | 天津国际生物医药联合研究院 | 2018-03-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | PNPO, G6PD, AGXT | TDP1 476/4885KDM4E 2866/4885MEN1 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.